AgenT-797

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides immitis NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced new clinical and translational data presented at the American Thoracic Society (ATS) International Conference 2026 and the simultaneous publication in Clinical Immunology Communications 1 describing the use of sequential immunotherapy with MiNK’s off-the-shelf iNKT cell therapy, agenT-797 and N-803, an IL-15 superagonist, in a critically ill patient with unresolving disseminated Coccidioides immitis infection, severe acute respiratory distress syndrome, and concurrent hospital- acquired Pseudomonas aeruginosa pneumonia . The poster, titled 'Novel Invariant Natural Killer T Cell (agenT-797) and Interleukin-15 Superagonist (N-803) Combination Immunotherapy for Unresolving Coccidioides immitis Infection with Concurrent ARDS ,' was presented by Terese C. Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics, and describes a sequential immunotherapy regimen pairing agenT-797, MiNK's investigational off-the-shelf iNKT cell therapy, with Anktiva® (N-803), an FDA-approved IL-15 superagonist developed by ImmunityBio, reflecting a combination strategy built on two clinically validated immune mechanisms. The patient was critically ill, facing a convergence of severe threats: disseminated Coccidioides immitis (valley fever) fungal infection, severe acute respiratory distress syndrome (ARDS), and concurrent hospital-acquired Pseudomonas aeruginosa bacterial pneumonia, all after standard-of-care antifungal, antibacterial, and supportive therapies had failed to halt clinical decline. Key Clinical and Translational Findings Following sequential treatment with Anktiva (N-803) and agenT-797, investigators observed: Suppression of both fungal and bacterial pathogens Active immune cell recruitment into the lung Reduced early inflammatory signaling Activation of tissue repair and immune regulatory pathways Immune profiling revealed a coherent biological sequence: Anktiva triggered early immune activation, followed by agenT-797-driven changes consistent with iNKT cell engagement, pathogen control, and a transition from inflammation toward resolution and repair. The pattern suggests the treatment sequence may have helped restore coordinated immune function in a patient whose infection and respiratory failure had continued to progress despite intensive intervention. “These observations are clinically and biologically important because they point to a pattern we are increasingly seeing across severe lung injury where immune failure itself may become a dominant driver of poor outcomes,” said Terese Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics. “As a practicing pulmonary critical care physician, what stands out in this case is not only the reduction in inflammatory signaling, but the evidence of immune recovery and pathogen control in a patient whose infection had persisted despite intensive antifungal, antibacterial and supportive therapy. Many critically ill patients do not decline from early inflammation alone. They deteriorate later from prolonged respiratory failure, secondary infections, immune exhaustion and multi-organ dysfunction. While this is a single case and must be interpreted with appropriate caution, the findings support the clinical question we are now studying prospectively, whether restoring immune competence can change the trajectory for patients with severe pneumonia, respiratory failure and critical illness.” The patient's family ultimately pivoted to comfort care due to recurrent cardiac decompensation in the setting of pre-existing mitral valve disease, acute mitral regurgitation and cardiogenic shock. The authors further supported this rationale in the ATS poster presentation, when chest imaging, clinical data including real time pulmonary arterial catheter and cardiac echocardiography data augmented post-mortem cytokine and biomarker results to prioritize acute heart failure rather than cytokine release or infectious contributions as the most likely mechanism. The ATS presentation and Clinical Immunology Communications publication build on MiNK’s prior clinical experience with agenT-797 in moderate to severe ARDS, where the therapy was associated with a favorable safety profile, improved survival rate and decreased secondary infection rates. The new findings also support MiNK’s broader platform thesis that iNKT cells may respond dynamically to the immune environment they encounter, with potential relevance across oncology, severe lung injury, persistent infection and immune dysfunction. Expanding on these findings, MiNK recently announced the initiation of a randomized Phase 2 clinical trial evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with severe acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure due to severe pneumonia, who meet Global ARDS criteria and are admitted to the ICU. The study is designed to prospectively evaluate agenT-797 in a defined critical care population where respiratory recovery, ventilator-free days, secondary infection and survival can be assessed using clinically meaningful endpoints. The full ATS poster will be available on the publications section of MiNK Therapeutics’ website following the presentation. References 1 Hammond TC, et al. Rapid suppression of unresolving disseminated coccidioidomycosis infection with combined IL-15 super-agonist (N-803) and invariant natural killer T cell therapy. Clinical Immunology Communications . 2026. doi:10.1016/j.clicom.2026.04.002 About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse. Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law. Contacts Investor Contact: 917-362-1370 | investor@minktherapeutics.com Media Contact: 781-674-4428 | communications@minktherapeutics.com Source : MiNK Therapeutics

Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease Non-dilutive collaborations expand MiNK’s platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programs Company continues disciplined execution with reduced operating burn and focused advancement of high-priority programs New clinical data to be presented at the ATS conference on May 20, 2026 NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported financial results for the first quarter ending March 31, 2026, and provided a corporate update. “MiNK entered 2026 focused on converting a growing body of clinical and translational evidence into prospective validation,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics. “During the first quarter and subsequent period, we advanced agenT-797 into a randomized Phase 2 study in acute lung injury and critical illness, presented data that further support the context-dependent biology of iNKT cells, and continued to expand the platform through selective, non-dilutive collaborations. This is the next phase of MiNK’s strategy: disciplined clinical execution, rigorous translational validation, and capital-efficient expansion of a broadly deployable cell therapy platform.” Dr. Buell continued , “What continues to distinguish agenT-797 is both its biology and its practicality. As an off-the-shelf iNKT cell therapy administered without lymphodepletion or HLA matching, agenT-797 is designed for settings where immune dysfunction drives poor outcomes and where speed, tolerability and deployability matter. We believe this is particularly relevant in severe acute lung injury and critical illness, where patients often face a cascade of respiratory failure, secondary infection and organ dysfunction with limited therapeutic options.” Recent Business and Development Highlights agenT-797 Advanced into Randomized Phase 2 Clinical Evaluation in Acute Lung Injury and Critical Illness MiNK initiated a randomized Phase 2 clinical trial evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with severe acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure due to severe pneumonia, who meet Global ARDS criteria and are admitted to the ICU. The study is being designed with a seamless Phase 2/3 operational framework intended to support efficient transition into later-stage development if findings from the randomized Phase 2 portion are prospectively confirmed. The trial has received authorization from the Ukraine Ministry of Health, is supported by an active U.S. IND, and remains subject to FDA clearance for planned U.S. site activation. Preliminary data are expected in the second half of 2026. Acute lung injury and ARDS remain among the most serious unresolved conditions in critical care. ARDS affects an estimated 3 million patients globally and approximately 200,000 patients annually in the United States, accounting for nearly 25% of mechanically ventilated ICU patients. i Mortality remains high, approximately 40% to 50%, and there are currently no approved pharmacologic therapies shown to reduce mortality in ARDS. ii The trial is designed to prospectively evaluate agenT-797 in a clearly defined, critical care population where ventilator-free days, secondary infection, respiratory recovery and survival can be assessed within clinically meaningful and regulatory-aligned endpoints. Recent Data at AACR and ASGCT Strengthen the Biologic Rationale for Context-Dependent iNKT Activity Recent clinical and translational presentations at the American Association for Clinical Research (AACR) Annual Meeting and the American Society of Gene and Cell Therapy Meeting (ASGCT) reinforced the potential of MiNK’s iNKT platform to generate disease-relevant immune activity across distinct clinical settings. In PD-1 refractory gastroesophageal cancer, investigator-sponsored Phase 2 data showed disease control and longer-term survival in a subset of heavily pretreated patients, supported by evidence of immune activation and tumor microenvironment remodeling. The study achieved a 77% disease control rate, with long-term survival beyond 20 months observed in a subset of patients with immune-induction prior to chemotherapy. These patients also had longer progression-free survival compared with those treated without induction, with median PFS of 6.9 months versus 3.5 months. At ASGCT, translational analyses showed that the same off-the-shelf agenT-797 product generated distinct immune outputs in solid tumor and ARDS patients. In solid tumor patients, agenT-797 was associated with a TH1 pro-inflammatory signature consistent with anti-tumor immune activation. In ARDS patients, the same product was associated with a TH2 anti-inflammatory signature consistent with immune restoration and lung injury recovery. Together, these findings support MiNK’s broader development strategy: advancing agenT-797 in settings where immune dysfunction contributes to poor outcomes, while using translational data to define patient populations, biologic mechanisms and future development pathways. Non-Dilutive Collaborations Support Capital-Efficient Platform Expansion MiNK continued to advance its strategy of expanding the iNKT platform through selective collaborations that provide external support and potential downstream economics while preserving focus on lead clinical programs. In the first quarter, MiNK announced a collaboration with C-Further , an international pediatric oncology therapeutics consortium enabled by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity, to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. The collaboration provides up to approximately $1.1 million in non-dilutive aggregate funding to support IND-enabling development, with potential meaningful double-digit downstream commercial revenue participation. The C-Further program applies MiNK’s off-the-shelf iNKT platform to a validated tumor antigen strategy in pediatric oncology and reflects the company’s broader approach to platform expansion through externally supported, capital-efficient development. MiNK is also advancing additional externally supported programs, including its graft-versus-host disease program supported by NIH STTR funding and the Mary Gooze philanthropic award. These collaborations and funding sources are intended to support pipeline progress while reducing the capital burden typically associated with multi-program cell therapy development. Upcoming ATS Presentation Extends Platform Discussion into Persistent Pulmonary Infection and Immune Dysfunction MiNK will present clinical data featuring agenT-797 at the American Thoracic Society (ATS) International Conference 2026. The presentation, titled “ Novel Interleukin-15 Superagonist (N-803) and Invariant Natural Killer T Cell (agenT-797) Combination Immunotherapy for Unresolving Coccidioides immitis Infection ,” will be presented by Terese Hammond, M.D., and in collaboration with ImmunityBio (NASDAQ: IBRX) on May 20, 2026 . In accordance with ATS guidelines, no data or results have been disclosed prior to the conference. The presentation is expected to expand the platform discussion beyond oncology and acute inflammatory lung injury into persistent infection, immune dysfunction and pathogen control, areas where MiNK believes immune restoration may have broader therapeutic relevance. Financial Results MiNK ended the first quarter of 2026 with approximately $9.5 million in cash and cash equivalents, compared with approximately $13.4 million as of December 31, 2025. During the quarter, the company completed repayment of approximately $5.2 million associated with the Agenus convertible note, further simplifying its balance sheet. Following this repayment, MiNK raised approximately $3.0 million through its at-the-market sales agreement during the three months ended March 31, 2026. Net loss for the first quarter of 2026 was approximately $2.7 million, or $0.57 per share, compared with approximately $2.8 million, or $0.70 per share, for the same period in 2025. Summary Consolidated Financial Information Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) March 31, 2026 December 31, 2025 Cash and cash equivalents $ 9,526 $ 13,360 Other Financial Information (in thousands) (unaudited) Three months ended March 31, 2026 2025 Net loss $ 2,742 $ 2,767 Net loss per share 0.57 0.70 Cash used in operations $ 1,733 $ 1,341 First Quarter 2026 Financial Results Conference Call and Webcast MiNK will host a conference call and webcast today at 8:30 a.m. ET to discuss its financial results and corporate update. Conference Call and Webcast Information United States – New York USA & Canada – Toll-Free Conference ID – (646) 307-1963 (800) 715-9871 4876136 Webcast & Replay Information A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event. Live event link: Webcast Replay: About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse. Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law. Contacts Investor Contact: 917-362-1370 | investor@minktherapeutics.com Media Contact: 781-674-4428 | communications@minktherapeutics.com Source: MiNK Therapeutics _________________________ References i Cleveland Clinic . Acute Respiratory Distress Syndrome (ARDS). ii Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries . JAMA . 2016;315(8):788–800.